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Approach to Risk Assessment for
Genotoxic Carcinogens Based on Data
from the Mouse Skin Initiation*Promotion
Model
by F. Burns,* R. Albert,* B. Altshuler,* and E. Morris*
Tumor induction data in the mouse skin initiation-promotion system were found to be consistent
with a quadratic function where the coefficient of the linear term depended on the dose of the pro-
moter. The model implies that the existence of promoters may be more important at low doses of the
carcinogen than at high doses where most testing is performed. Experiments are described show-
ing that the initiating effect of carcinogenic chemicals, such as benzo(a)pyrene, 7,12-dimethyl-
benz(a)anthracene, nitroquinoline oxide and P-propriolactone, accumulates in a linear, irreversible
manner at low doses. Even when 7,12-dimethylbenz(a)anthracene was applied intragastrically to
pregnant females, initiating activity was found in the skins of exposed offspring about in proportion
to dose applied and number of cells at risk. The initiated cells essentially represent a potential for
cancer that has a high probability for expression in the presence of a promoter.
Risk then can be interpreted in terms of the accumulated dose of initiator which alone presents
a small risk of cancer. However, a promoter may substantially expand the overall risk, possibly by
clonally expanding the initiated cells. Promotion needs to be sustained since there is a reduction of
cancer risk if promotion is ended early. Some tissues, such as mouse bladder, may be intrinsically
promoted more than others so that comparisons between tissues and between species are best made
when the combination of intrinsic promotion and response to extrinsic promotion are comparable.
Introduction
In an attempt to explain mouse skin tumor data
in terms of multistage progression, we have formu-
lated a cell generation hypothesis (1-3). In this for-
mulation, the initial event in carcinogenesis is as-
sumed to be an interaction between the carcinogen
and the cell (probably the DNA of the cell) that
changes the cell in such a way that it is identifiable
as initiated, i.e., it forms a benign clonal growth,
known as a papilloma, when exposed to a promoter,
such as, 12-0-tetradecanoylphorbol-13-acetate (TPA)
(4,5). Furthermore, it is assumed that the original
initiated cell and all of its progeny are unstable in
the sense that they are subject at each cell division
to the risk of additional changes leading to progres-
sive acquisition of cancerous properties (6).
Papillomas that are dependent on continued pro-
motion, i.e., those that would regress if the promo-
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tion were stopped, may acquire autonomy (4). The
cells in autonomous papillomas continue to be at
risk of progression to cancer whether or not promo-
tion is continued. Probably many changes not pro-
duced directly by the carcinogen are needed to con-
vert an initiated cell into a cancer cell. These addi-
tional changes or transitions are an indirect result
of initiation and are assumed to be distributed in a
stochastic manner in time subsequent to initiation
(Fig. 1)
Multistage theory holds that the value of the ex-
ponent of the function of tumor rate versus time
equals the number of stages in carcinogenesis. Ac-
cordingly, that exponent ought to be constant, but
there are many examples where it varies. This can
be handled by invoking clonal expansion as an im-
portant determinant of the temporal function when-
ever promotion, intrinsic or extrinsic, is present (6).
Thus, there are two routes a cell may take as it pro-
gresses to cancer. The first route involves one car-
cinogen-induced alteration (initiation) followed by
additional alterations that are observable only be-BURNS ETAL.
cordingly, the cumulative probability per unit time
of cancer occurrence, often referred to as the cumu-
lative hazard functionH(Ud) can be written:
n
H(t,d) = TI Kitn
i= 1 (2)
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FIGURE 1. Schematic diagram of the multistage-multi-
generational hypothesis. The initial event is depicted as
being produced by a carcinogen (arrow with C). In the up-
per panel the cell (1,0) with one event multiplies into a clone,
and at a subsequent cell division suffers a spontaneous
event (arrow with S) to become a cell that is equivalent to
one having suffered two carcinogen induced (without
clonal multiplication) events as depicted in the lower panel.
The further progression of 1,1 cells is depicted as requir-
ing four additional events. As discussed in the text, this
number is somewhat uncertain, because it depends on the
amount of clonal multiplication assumed for intermediate
stages.
cause of the multiplication of probability implicit in
clonal growth. The second route involves two or
three carcinogen-induced alterations that presum-
ably damage the cell so severely that additional al-
terations are probable even without substantial
clonal growth.
To make these ideas more concrete, we can for-
mulate them into a mathematical framework. First
let it be assumed that cancer requires n stages.
These stages correspond to transitions that can be
described by transition probabilities (for the i-th
transition) of the form:
Ki= at+bd (1)
where ai is the spontaneous transition rate, bi is the
dose coefficient of the i.th transition and d is the
dose of the carcinogen (2).
Ifai and bi are constants and the dose rate is con-
stant, the cumulative probability of the i-th transi-
tion is given by Ki t where t is elapsed time. Ac-
For any transition where the spontaneous rate is
negligible in comparison to the carcinogen-induced
rate, i.e., ai<<b d, the transition probability can be
written as bid. If there are m such transitions, the
cumulative hazard becomes:
m n
H(t,d) = TI bi IT K.dmtn (3)
i=1 i=m+1 )
Since the tumors are assumed to be randomly dis-
tributed among the animals, the proportion with tu-
mors, O(t,d), is related to the cumulative hazard,
H(t,d), by the equation:
P(t,d) = 1 - e -H(t,d) (4)
It follows that 50% of any given group of animals
will have at least one tumor when H= 0.693 (8). If
the time when 50% have developed at least one tu-
mor is designated t., it follows from Eq. (3) and (4)
that:
d t.,n/m = constant (5)
Equation (5) can be considered to be a dose-response
function where m is the number of dose-dependent
transitions and n is the total number of transition in
carcinogenesis.
Equation (5) was originally found empirically by
Druckrey to apply to liver carcinogenesis when
either AAF or DEN were given in the diet, and the
value of n/m was estimated to be about 2.3 (9). Val-
ues of n/m were derived from the epidemiological
data on lung cancer in cigarette smokers and found
to be 2.6 (10). The multistage theory seems general-
ly to fit the experimental and epidemiological data
quite well for situations where the carcinogen expo-
sure is prolonged, and the dose rate is constant.
The principle defect of the multistage theory is
that the stages are not identifiable and their order
or sequence is unknown. Peto concluded that the
carcinogen-dependent stages were probably early in
the sequence because older mice, that presumably
had accumulated many of the non-carcinogen re-
lated stages,-showed no greater response to topical.
application of a carcinogen, benzo(a)pyrene, than
younger mice (11). The stages themselves are pure-
ly speculative entities but certainly can encompass
the concept of carcinogenic progression as it is cur-
rently understood. Cancer cells may need to acquire
a number of specific properties, such as the ability
to stimulate host blood vessels by means of angio-
genesis factor, the ability to dissolve connective tis-
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sue proteins by secreting proteases, the ability to
block the immune defenses of the host by producing
blocking factor. The acquisition of each of these
properties occurring sequentially in a given period
of time could be considered to represent transitions
between stages in the multistage model. Of course,
there are many other properties of cancer cells that
might represent stages and certainly more biologi-
cal studies are needed to refine our understanding
of stages and the transitions between them.
The mouse skin is an ideal model system to test
these ideas and to study dose and time related as-
pects of benign and malignant tumor formation. A
series of experiments were performed in an at-
tempt to answer certain specific questions related
to these ideas. The first and most important ques-
tion was what shape to assume for the dose-re-
sponse function of benign and malignant tumors.
Animals were observed every other week and
the progress of individual tumors was charted. Re-
gression of tumors and progression of benign le-
sions to malignancy was noted. Animals were sacri-
ficed when moribund or when tumors exceeded 1.0
cm3 in size. Representative benign skin tumors and
all carcinomas diagnosed grossly were excised,
fixed in 10% formalin and blocked in paraffin. Slides
were prepared and stained with hematoxylin and
eosin for histopathological diagnosis.
For each observation interval, the number of new
tumors was divided by the average number of mice
alive to obtain the rate of tumor occurrence. The
rates were added cumulatively to obtain the yield of
tumors in tumors per mouse (cumulative hazard) as
a function of time.
Figure 2 shows the yield of papillomas and carci-
nomas in mice receiving only TPA thrice weekly.
These data are based on 63 mice. Median survival
was 550 days and there were 7 mice left at 650
days. Papilloma formation began at 150 days after
the start of promotion and increased continuously
thereafter. All carcinomas appeared from pre-exist-
ing papillomas. The conversion of papillomas to car-
cinomas was initially evident at 350 days and con-
tinued thereafter with a ratio of papillomas to carci-
nomas at about 7:1. No tumors were observed in 40
acetone treated mice during the same period of
time.
Figure 3 shows the papilloma and carcinoma yield
after a single initiating dose of 128 Mg B(a)P followed
by TPA thrice weekly. The temporal pattern is typ-
ical of that for other initiating doses of B(a)P. Papil-
loma formation began at about 50 days and contin-
ued fairly steadily thereafter. A few carcinomas de-
veloped from pre-existing papillomas beginning at
about 350 days.
The temporal pattern of tumor formation after
single and multiple applications of B(a)P as an ini-
tiating agent are similar. These data are shown in
Figure 4.
The lack of fractionation effect permits the dis-
play shown in Figure 5 of the tumor response per
fractional dose. For example, if 128Mg were given in
eight fractions with a tumor incidence of 5.3 tumors/
mouse at 200 days, the net tumor yield per fraction,
(5.3- 0.06)8 = 0.66, would be plotted against the
dose per fraction. 128/8 =16. Figure 5 shows these
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FIGURE 2. Yield of (e) papillomas and (o) carcinomas in
mouse (Ha/ICR) skin treated only with 5 pg TPA in 0.2 mL
acetone three times weekly.
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FIGURE 3. Cumulative yield of (*) skin papillomas and of (o)
skin carcinomas after topical treatments. A single dose of
128 Mg B(a)P administered at 56 days of age was followed
by treatment three times weekly with 5 ,ug TPA in 0.2 mL
acetone.
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data for all single and fractionated exposures. The
regression line drawn through the data points has a
slope of 0.90. The data support the linear dose-re-
sponse relationship of papilloma formation for B(a)P
initiation throughout a dose range extending three
orders of magnitude. The slope is such that one ini-
tiated tumor site is produced by each 30 pg dose of
B(a)P.
The data support the linear nonthreshold charac-
ter of the dose-response relationships for the initia-
tion of carcinogenesis by B(a)P in the mouse skin. A
linear nonthreshold dose-response was also obtained
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from B(a)P in the skin of Sencar mice at a dose of 2
,g TPA twice a week (12). The lack of a fractiona-
tion effect is consistent with the linear response to
single carcinogen exposures and implies a mecha-
nism based on a single irreversible event.
If each papilloma is considered to be a clonal ex-
pansion of an initiated cell, and an initiated cell is
the first stage in carcinogenesis, the above data per-
mit an evaluation of_K1 =a,+ b1D. For example,
from the data in Figure 2, a1=(0.5/575) transi-
tions/mouse/day and from the data in Figure 5,
b,= (2/16000)transitions/mouse-.g-day.Thepatternof
papilloma induction and conversion of papillomas to
carcinomas in the uninitiated mice treated thrice
weekly with TPA suggests that the skin has a back-
ground of initiation equivalent to about (4000/575) Mg
of B(a)P, i.e., ajb1. Since the area of mouse skin
treated contains about 3 x 106 epidermal cells, the
corresponding transition constants in units of transi-
tions per cell per day are af'= 290 x 10-12 and b
=42 x 10-12 in transitions/cell Ag day.
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The dose dependency of the binding of ben-
zo(a)pyrene [B(a)P] with DNA of mouse epidermis
I I was investigated. B(a)P-conjugated epidermal DNA
120 160 was isolated and enzymatically degraded to deoxyri-
*g) bonucleosides. The B(a)P-DNA adducts were sepa-
rated by Sephadex LH-20 column or high-perfor- ays of promotionasea mance liquid chromatography. Two major B(a)P-
br of fractions as indi- DNA adducts were found. One was in the region of
-d weekly. the elution profile that contained polycyclic aromat-
ic hydrocarbons adducted to deoxyribonucleosides.
The other adduct was eluted from Sephadex LH-20
Df / and high-performance liquid chromatography col-
umns before the deoxyribonutcleosides and after de-
oxyribonucleotides. Both adducts of B(a)P in epider-
,Sh mal DNA reached a maximum 7 hr after a single
0 skin application, and subsequently little, if any, loss
of adducts was observed for 49 hr. Both adducts
varied as a linear function for topical doses in the
range from 0.01 to 300 Mg/mouse. The formation of
DNA adducts by B(a)P occurred in proportion to
dose at doses several orders of magnitude below
* Single Dom those that are feasible to test for carcinogenicity.
o Multiple Doses When B(a)P is applied to mouse skin (13), added
to cell culture (14) or incubated in the presence of
Ill I microsomes and DNA (15), electrophilic metabolites
10 100 are formed that covalently bind to DNA. The initia-
tion of carcinogenesis by polycyclic aromatic hydro-
carbons is believed to involve covalent binding to
se per fraction. The cellular macromolecules, and there appears to be an
alysis and indicates a especially good correlation between their carcino-
genic potency and DNA binding (13). Thus, the bind-
0
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ing to DNA might serve as a sensitive indicator of
carcinogenicity since analytical techniques are avail-
able to detect such binding at extremely low doses.
Actually, the formation of a number of different
DNA adducts as well as tritium exchange onto the
bases is possible. Thus, specific B(a)P:DNA adducts
could serve as a better marker for biological po-
tency than the total amount of binding in B(a)P-con-
jugated DNA. The major hydrophobic B(a)P adduct
to deoxyribonucleosides formed in vivo has been
identified and studied extensively (16,17). Hydro-
philic B(a)P:DNA adducts present in the elution pro-
files obtained from the chromatography systems
used in the isolation of B(a)P:deoxyribonucleoside
adducts remain to be characterized (18).
Promotion in Combination with a
Carcinogen
Promoters have important consequences in deter-
mining the temporal pattern of cancer induction by
accelerating the development of neoplasia. Promo-
ters may act by stimulating clonal expansion of po-
tentially cancerous cells, or they may stimulate the
expression of a neoplastic event or they may actu-
ally produce neoplastic events. In order to deter-
mine the temporal effect of promoters on carcino-
genesis, mouse skin was exposed to weekly doses of
benzo(a)pyrene either alone or in combination with
various twice weekly doses of TPA. The cancer
yield as a function of time when B(a)P was given
alone is shown in Figure 6. As the B(a)P dose in-
creased from 16 jg weekly to 128 ,g weekly, the tu-
mor curves were displaced progressively to earlier
times in such a manner that n/m in the expression,
BaP
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FIGURE 6. Cumulative yield of skin carcinomas per mouse.
Numbers identifying each curve indicate the topically
applied weekly dose of B(a)P treatment at 56 days of age.
dtgvnlm= constant, was about 2.1, where d was week-
ly dose and t. was time to 50% prevalence.
The results when various weekly doses of TPA
were added to a given weekly dose of B(a)P are
shown in Figure 7. As the TPA dose was increased,
the cancer yields were progressively displaced to
earlier times, although there seemed to be a plateau
effect in the sense that the increase from 0.5 to 5.0
,ug per week produced much less displacement than
the increase from 0.05 to 0.5 pg per week. There is
little doubt from these data that TPA, a promoter
of papillomas, accelerated the development of carci-
nomas. The maximum degree of temporal displace-
ment (the highest TPA dose) was equivalent to a 4-
fold increase in B(a)P dose. These data suggest that
part of the temporal displacement associated with
different doses of B(a)P could be derived from the
promoting action of B(a)P.
A dose-effect relationship for carcinoma induction
under conditions of repeated weekly B(a)P exposure
can be generated by considering the tumor yield at
a specific point in time, specifically 300 days after
the B(a)P was started. These data are shown in Fig-
ure 8. In the absence of TPA, the cancer yield in-
creased sharply with dose consistent with a squared
or cubed function. However, when TPA was added
weekly along with B(a)P, the dose effect function
shifted markedly to the left, i.e., to lower B(a)P
doses, and more importantly lost the squared or
cubed dose dependence and became nearly linear.
One explanation of these data is that papillomas
contain cells, probably a clonal expansion of cells,
that have undergone one or more events, presum-
ably involving damage to DNA, that are early
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FIGURE 7. Cumulative yield of skin carcinomas per mouse.
Each animal received weekly treatments of 16 jlg B(a)P
(Monday) plus twice weekly treatments of 0, 0.5, 0.5, or 5.0
Mg TPA (Wednesday and Friday). Chemicals were topically
applied in 0.2 mL acetone.
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FIGURE 8. Dose-effect data at 350 days for carcinoma induc-
tion in mouse skin exposed to a weekly dose of B(a)P on
Monday with or without 5.0 ,ug TPA on Wednesday and
Friday. Doses refer to the amount of B(a)P given per week.
The treatments were started at 56 days of age.
events in the production of a cancer cell. It is not
suggested here that every event presumed to be in-
volved in carcinogenesis necessarily produces cells
that are expandable into clones by the action of
phorbol ester. Neither can we eliminate the possibil-
ity at the present time that the promoter may have
effects in addition to stimulation of clonal expansion,
although such events must differ from initiator-
induced events.
One hypothesis consistent with these data is that
one or two events, e.g., chromosome breaks, pro-
duced either directly or indirectly by the action of a
carcinogen, cause an instability leading to the accu-
mulation of additional changes, possibly as many as
four to six (19). Presumably any or all of these
events may occur spontaneously, which is necessary
to explain the occurrence of "spontaneous" cancer in
untreated animals and the conversion of persisting
papillomas to cancers without further treatment.
The clonal expansion implicit in the growth of a pa-
pilloma greatly increases the chance that cancer will
occur, because each papilloma cell has a spontane-
ous risk of occurrence of later events, including
some that could be produced by action of a carcino-
gen. The promoter may also fix the initiation since
short exposure to a promoter followed by a mitotic
stimulation will produce tumors, whereas mitotic
stimulation alone will not.
The shapes of the dose-effect functions for car-
cinoma induction with and without promotion can
be explained in terms of the above ideas as follows.
In the absence of promotion the carcinogen must
act directly and repeatedly on target cells to pro-
duce whatever number of events are necessary for
a malignant cell to occur (possibly two or three);
hence the yield of cancers is proportional to (dose
rate)2-3, and a relatively high total dose is needed to
produce a given yield. If the tissue is promoted,
clonal expansion of some intermediate state leads to
a greatly increased overall risk of malignancy be-
cause each initiated cell in a papillomatous clone is
assumed to have acquired some risk, albeit small, of
the occurrence of additional events that would com-
plete the transition to malignancy. Cancers derived
from such papillomas would be expected to follow
the dose-response characteristic of the papillomas,
since second and subsequent events would occur
spontaneously without the necessity for action by
the carcinogen. The cancer yield for a given dose of
carcinogen would be much higher with promotion
than without because of the risk multiplication in-
herent in clonal expansion.
The data in Figure 2 show that the rate of con-
version of spontaneous papillomas to carcinomas
was about 1/300 per day, while the data in Figure 3
show the comparable rate for induced papillomas
was about the same (1/350 per day). If all papilloma
cells are at risk, these values reduce to transition
rates of about (1/300-350) x 10-6 per cell per day,
since there are about 106 cells per papilloma. In our
model the latter quantity is an estimate of a2, the
spontaneous rate of transition of papillomas to a cell
type that has a high risk of further events in the
progression to cancer.
Interactions between Initiators
Given that the neoplastically related cellular dam-
age is not precisely known and that carcinogenic
chemicals are chemically diverse, it is important to
establish whether cells initiated neoplastically by
one carcinogen exhibit differences in their interac-
tion with a second carcinogen. Since single initiated
cells cannot yet be isolated and studied, it is neces-
sary to study interactions by applying carcinogens
to whole tissues. The initiation-promotion system in
mouse skin is one of the most useful for studies of
this type (7). The objective of the study described
here was to determine how the several chemically
diverse initiators interacted when applied at differ-
ent times to the same region of dorsal mouse skin.
The purpose of these experiments was to deter-
mine whether different classes of chemical carcino-
gens produce additive yields of papillomas when ap-
plied sequentially to mouse skin. The carcinogens
were benzo(a)pyrene, nitroquinoline oxide (NQO)
and P-propriolactone (BPL) applied topically to the
shaved dorsal skin of mice (Ha/ICR) in 0.2 mL ace-
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tone. The papilloma yield as a function of promotion
time is shown by the open triangles in Figure 9 for
mice that received 6 mg BPL and 16 ig B(a)P. The
summation of the yields for separate groups of mice
that received 6 mg BPL or 16 ,ug B(a)P as single
doses is indicated by the closed triangles. The com-
bined exposure produced about twice as many papil-
lomas as expected from the summation of the indi-
vidual single doses. No carcinomas were observed.
The papilloma and carcinoma yields for ,ug NQO
and 16 ,ug B(a)P are shown in Figure 10. Here the se-
quence of administration markedly affected the
yield of tumors. NQO prior to B(a)P produced about
Initiation -Promotion
6mg BPL+16tLg BaP
A Observed
A Expected
the same yield of papillomas as the summation of
the yields for the individual exposures. However,
the yield of carcinomas was much greater than ex-
pected from the summation of yields from the indi-
vidual exposures. When the sequence was reversed
(B(a)P first), the yield of papillomas was about the
same as that produced by either a single dose of
NQO or B(a)P alone. Only about 50% of the yield ex-
pected from the summation of the single-dose yields
was realized by administering B(a)P before NQO. In
marked contrast to the NQO-first sequence, no car-
cinomas were observed.
The papilloma yield as a function of promotion
time is shown in Figure 11 for single doses of BPL
as indicated. The yield reached a peak at about 100
days and declined slowly thereafter until a fairly
stable level was reached beyond 250 days. The 48
mg yield was about twice as great as the 24 mg
yield throughout the experiment. Carcinomas began
to appear after 350 days.
The dose response at 200 days of promotion for
single and split doses of BPL is shown in Figure 12.
The yield of papillomas versus dose is reasonably
100 200
Time (days)
FIGURE 9. Plots of (A) the incidence of skin papillomas per
mouse following initiation with 6 mg BPL plus 16 pg B(a)P
and (A) the numerical summation of the yields in groups of
mice given single doses of 12 mg BPL or 16 ;Ag B(a)P. All
animals were promoted with 5 Mg TPA three times per
week.
s
n9 U,1
t,
V)
W -
cn E
m
0 100 200 300 400 500
Time (days)
FIGURE 10. Incidence of skin papillomas (left) and carcinomas
(right) per mouse observed following skin painting. Topical
carcinogen treatments involved either a single dose of
B(a)P or a single dose of either NQO or B(a)P followed two
weeks later by another single dose of either NQO or B(a)P
(whichever had not been applied the first time). Thrice
weekly topical treatments with 5,g TPA began one week
after initiation.
10 100 200 300
Time(Days)
FIGURE 11. Yield of papillomas (average number of tumors
per animal) as a function of promotion time. Single doses
of p-propiolacetone (BPL) were given at 56 days of age fol-
lowed by promotion with 5 jAg TPA three times weekly.
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FIGURE 12. Yield of (left) papillomas and (right) carcinomas
(average number of tumors per animal) as a function of ap-
plied dose of BPL. The papilloma yield at 200 days is plot-
ted on the left scale and the carcinoma yield at 500 days is
plotted on the right scale.
well fitted by a linear function, and the split doses
produced up to 70% more papillomas than the cor-
responding single dose. Split doses produced as
many as 10-fold more carcinomas than correspond-
ing single doses.
The results reported here suggest that different
carcinogens given far enough apart in time that
chemical interaction is unlikely may interact in com-
plex ways depending on the carcinogens. Even the
same carcinogen may interact with earlier doses of
itself to either enhance, as for BPL, or inhibit, as for
NQO, the induction of papillomas by a promoter.
Extensive evidence reported above indicates that
polycyclic aromatic hydrocarbon, benzo(a)pyrene,
produces papillomas in proportion to dose even
when the dose is split into as many as 32 different
fractions. From these results, B(a)P appears not to
interact with earlier doses of itself.
It is difficult to explain results as seemingly di-
verse as these without considering the component
processes of the carcinogenic mechanism (5). If initi-
ation were the only effect being produced, the order
of administration of two carcinogens ought not to
matter. However, if one compound, e.g., NQO, were
to have promoting activity relevant to B(a)P, then
NQO prior to B(a)P ought to be more effective than
vice versa. This effect was observed, especially with
regard to carcinoma incidence. On the other hand,
B(a)P or BPL could have approximately equal pro-
moting activity relative to one another, since they
were more effective in producing papillomas when
given together in comparison to the summation of
their individual effects. Since the enhancement ob-
served here is inducible by a single exposure to the
second initiator, the events involved could be analo-
gous to what has been called the second stage of
promotion (20).
It is not likely that B(a)P, NQO or BPL applied to
skin persist in significant quantities after a few
days, so that very little is expected to be present
after one or two weeks. However, since inducible
enzyme systems may persist after the inducing
chemical is gone, the subsequent application of
another chemical requiring activation after a dose
could be influenced by a residual inducible enzymes
still present at the time of the second application.
Direct acting carcinogens, e.g., BPL and NQO, do
not depend for their carcinogenic activity on en-
zyme activation, so the enhanced yield seen with the
combination of these chemicals and B(a)P is prob-
ably not related to enzyme induction.
Progression of Papillomas to
Carcinomas
Papillomas are focal, benign lesions consisting of
folded layers of rapidly dividing cells that differen-
tiate into squamous keratinizing cells almost as rap-
idly as they are produced (21). Such lesions may per-
sist for many months growing slowly, other may re-
gress, and still others may develop into invasive
carcinoma (22). The latter papillomas are especially
interesting in carcinogenesis. Generally about 5 to
7% of the papillomas underwent malignant conver-
sion within the observation period (300 days).
Papillomas induced by initiation-promotion of
mouse skin exhibit a spectrum of neoplastic proper-
ties in their ability to grow independently of the
promoting chemical and their tendency to undergo
conversion to carcinomas. Not unexpectedly, the
greatest tendency for conversion to carcinomas was
found among the papillomas with the greatest de-
gree of autonomy, i.e., those having the least ten-
dency to undergo regression when the promoting
chemical is stopped.
Papillomas may be conceived of as clonal expan-
sions of initiated cells, and the results here indicate
that such cells, especially in autonomous papillomas,
have a fairly high probability of undergoing malig-
nant transition. It is not unreasonable to postulate
that the precursor cells of the papillomas, i.e., the
original initiated cells, retain the same probability
of malignant transition as the cells in the papil-
lomas. Since papillomas contain at least 105 cells,
their overall probability of malignant transition
would be at least that much greater than that of sin-
gle initiated cells, and corresponding cancers would
be expected earlier and with greater frequency in
the papillomatous tissue. Obviously, more work is
necessary to test such ideas, but the skin papilloma
clearly provides an excellent model for studying the
benign-to-malignant transition.
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Prenatal Initiation of Skin Cells
It is known that exposure of a pregnant animal to
carcinogenic chemicals is capable of producing a
neoplastic response in her progeny, even without
additional carcinogen treatment (23, 24). However,
comparatively little quantitative information is
available concerning the effect of carcinogens on
fetal cells at various periods of fetal development or
to what extent growth and development affect the
probability of a cell initiated in the fetus persisting
and expressing its neoplastic potential in the adult
organism.
In essence, this experiment was designed to de-
termine if exposure to a carcinogen during fetal de-
velopment results in initiated cells that can be pro-
moted to form tumors in the same way and extent
that has been found in adult skin. The goal of these
experiments was to determine if fetal initiation
could survive the dilution effect of the multiple cell
divisions involved in development without altera-
tion. These experiments were also aimed at obtain-
ing information on the relative susceptibility of the
fetal mouse skin at various periods of development
and of adult skin to the tumorigenic effects of
DMBA.
For each cell in the differentiating epidermal
basal layer of the 9-day mouse fetus, there are at
least 10 cells in 12-day fetus, 27 cells in the 15-day
fetus, 63 cells in the 18-day fetus and 428 cells in the
adult epidermal basal layer. In arriving at these rel-
ative numbers of cells, it was assumed that the rele-
vant cells are contained in a monolayer covering the
outer surface of the animal, that shape was not sig-
nificantly changed by the growth, and that the num-
ber of cells was proportional to surface area.
Pregnant Ha/ICR Swiss mice were treated by
gavage with DMBA on various days of gestation.
Ten male and ten female offspring were obtained
from mothers in each dose group. For the intragas-
tric treatments, the powdered DMBA was freshly
mixed with sesame oil (Erewhon, Cambridge, Mas-
sachusetts) on each treatment day. An 0.2 mL ali-
quot of the DMBA-sesame oil preparation was deliv-
ered via gastric intubation with a syringe fitted
with a feeding needle. For the topical treatments,
the DMBA was dissolved in acetone (Fisher Scien-
tific Company, Fair Lawn, NJ) and applied with a
Biopette (SchwarzlMann, Orangeburg, NY). All car-
cinogen treatment occurred between 8:00 A.M. and
10:00 A.M.
Caeasarean sections were performed on the preg-
nant mice on the afternoon of the nineteenth day of
gestation. The offspring of the treated mothers
were nursed by untreated foster mothers, who had
given birth several days previously. The offspring
were weaned at 4 weeks of age and were randomly
assigned to one of the two secondary treatment
groups.
The secondary treatments consisted of thrice
weekly topical application of either 0.2 mL acetone
(Fisher) of5Mg TPA in 0.2 mL acetone beginningat 9
weeks of age. Treatment of pregnant mice with
DMBA on day 15 of gestation produced skin tumors
in their promoted offspring at all of the doses
tested, 1, 2, 4 and 9 mg. No papillomas were ob-
served in the acetone-treated or TPA-treated con-
trol groups. The time response of papilloma devel-
opment in the offspring of mothers exposed to
DMBA is shown in Figures 13,14 and 15. These fig-
ures show that the first tumors appeared between
weeks 6 and 8 of promotion in all groups. Figure 13
also shows that mice whose mothers received 8 mg
DMBA developed fewer tumors than the offspring
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FIGURE 13. Time response of papilloma development follow-
ing initiation with DMBA on day 15 of gestation.
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FIGURE 14. Time response of papilloma development follow-
ing intragastric treatment of adults with DMBA. Experi-
ment ended at 16 weeks because of high incidence of lym-
phoma.
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of mice who received 4 mg DMBA. With the excep-
tion of the highest dose group, Figure 13 illustrates
that reduction of DMBA dose results in a decrease
in the multiplicity of tumors and total tumor yield.
The low tumor yield obtained from the highest
dose group may be attributed to a generalized toxic
effect. This dose produced some uterine bleeding,
premature delivery, stillbirths and neonatal deaths.
When the yield of papillomas was plotted against
dose (Fig. 16) or of epidermal cells (Fig. 17) in a
given region of skin (the region receiving promotion
in adults) for a given amount of intragastric carcino-
gen, a proportionality was obtained. Autoradio-
graphic studies showed that the amount of carcino-
gen in the epidermal or presumptive epidermal cells
varied very little between various stages of embry-
onic development and adults. These data are consis-
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FIGURE 15. Time response of papilloma development follow-
ing topical initiation of adults with DMBA.
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FIGURE 16. Dose response of papillomas at 13 and 27 weeks
of promotion following topical application of DMBA to
adults.
tent with the concept that the risk of initiation per
cell per unit dose is constant and that the tumor
yield is proportional to the number of cells in the
skin at time of exposure because a constant fraction
of the cells are exposed to the risk. Furthermore,
these data show that the initiated cell can survive
and presumably transmit its initiated state to prog-
eny in spite of a considerable amount of prolifera-
tion, growth and development from a 9 day embryo
to adult.
This concept is similar to the idea proposed to ex-
plain an association between an increased tumor in-
cidence and carcinogen exposure at later times of
fetal development when more cells would be pres-
ent (24). These workers suggested that the greater
number of cells present at later times of fetal devel-
opment was the basis for the enhanced tumorigenic
response.
Conclusions
The model outlined here is tentative in the sense
that additional confirmatory studies are necessary
to define more pecisely the distinction between car-
cinogen-induced and spontaneous events and the
role of clonal growth in whole carcinogenesis, and
its applicability to organs other than skin is uncer-
tain. Nevertheless there are several important and
testable implications of the model at low carcinogen
doses where considerable regulatory concern cur-
100 4mg DMBA
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Number of CelIs
FIGURE 17. Tumor yield expressed as a function of the rela-
tive number of cells present at the time of exposure to 4
mg DMBA. In ascending order, the data points are for 9,
12, 15 and 18 day embryos and adults.
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rently exists. One inevitable implication of the
model is that as long as a, and a2 are not zero, there
must exist a region of dose where the dose-response
function is linear. In-the absence of promotion, the
linear dose region is defined by the magnitude of
the various transition constants, since the yield
function has the form
y = constant (a1 + b,d) (a2 + b2d)
'va1a2 + (a2b1 + a,b2)d
However, the clonal growth of cells containing the
first transition effectively amplifies the value of a1
and b1 so that in the extreme as observed in our ex-
periments the dose-response function becomes lin-
ear even at high doses. Clearly there must exist an
intermediate situation where linear and dose-
squared (or higher) terms coexist. The region of co-
existence will be defined largely by the amount or
intensity of the promotion. The model implies that
the general dose-response function has the form
Y= (constant) (A +Bd+ Cd2) where the magnitude
of the constants A, B and C depends on promotion
and/or clonal growth of one-event cells. Further-
more, the model implies that the constant may also
be promoter dependent, because all additional non-
independent events necessary to complete the tran-
sition to a cancer cell occur at a certain rate or prob-
ability in each cell generation, i.e., at each mitosis.
Hence, an increased mitotic rate is expected to in-
crease the rate of occurrence of such transitions.
In addition, clonal growth of two-event cells could
affect the time function so that extreme care must
be exercised when interpreting the exponent on the
time function in terms of the number of events in
carcinogenesis. At best, the exponent represents
the upper limit of the number of events that might
be involved but to the extent that clonal growth of
intermediate stages is involved the exponent could
reflect such growth. Since clonal growth is presum-
ably stimulated by the action of promoters, these
ideas emphasize the overriding importance of pro-
motion and promoters in the temporal functions of
cancer incidence.
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